

CURRICULUM VITAE

CURRICULUM VITAE EUROPASS



PERSONAL INFORMATION

Name and Surname

Tiziana Schioppa

Email

tiziana.schioppa@unicamillus.org

EDUCATION AND TRAINING

- Date 23/06/2021
- Institution Università degli Studi di Brescia.
- Title **Specialization in Pathology and Clinical Biochemistry**, University of Brescia.
Thesis: "The atypical receptor CCRL2/ACKR5 is a crucial player in the regulation of lung cancer immunosurveillance."
- Date 13/09/2006
- Institution Open University, London in collaborazione con l'Istituto di Ricerche Farmacologiche Mario Negri, Milano.
- Title **PhD**
Thesis: "Effects of tumour hypoxia on cell migration". Responsible of the studies Dott. A. Sica; supervisors: Prof. F. Balkwill, Prof. J. Pease.
- Date June 2004
- Institution Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Title **Specializzazione post diploma in ricerca farmacologica**
- Date December 2001
- Institution
- Title **Abilitazione alla professione di Biologo** (n° iscrizione all'Albo dei Biologi AA_090490)
- Date 7/11/2000
- Institution Università degli Studi di Padova
- Title **Laurea in Scienze Biologiche**
Titolo Tesi: "Clonaggio e caratterizzazione delle subunità dell'emocianina di *Carcinus aestuarii*". Supervisore Prof. B. Salvato, Correlatore Prof. F. Argenton.

WORK EXPERIENCE

- Date (from – to) **01 July 2025 - present**
 - Institution UniCamillus-Saint Camillus International University Of Health Sciences
 - Position Associate Professor

- Date (from – to) **November 2024-June 2025**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
 - Position Assegnista di Ricerca
 - Main role Project: Characterization of non-coding RNAs released by genetically altered cells related to Aicardi Goutieres syndrome. Tutor: Prof.ssa Daniela Bosisio.

- Date (from – to) **March 2023-October 2024**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia
 - Position Assegnista di Ricerca
 - Main role Project: “CCRL2 in tumor progression”. Tutor Dott.ssa Valentina Salvi.
In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of inflammation-induced carcinogenesis of the colon (AOM/DSS) and in genetic models (TP53/KRas) of lung cancer.

- Date (from – to) **Marche 2020-February 2023**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università degli Studi di Brescia, Italia
 - Position Fixed term Researcher (RTDA), SSD 06/A2 “Patologia Genarale e Patologia Clinica”, MED/04 “Patologia Generale”.
 - Main role In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colon inflammation-induced carcinogenesis (AOM/DSS) and in genetic models (TP53/KRas) of lung cancer.

- Date (from – to) **January 2020-February 2020**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università degli Studi di Brescia, Italia
 - Position Assegnista di Ricerca
 - Main role Project: "New molecular targets to control the production of type I interferon in psoriasis". Tutor Prof. Daniela Bosisio

- Date (from – to) **January 2019-December 2019**
 - Institution Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia, Italia.
 - Position Research fellow (Borsa di Ricerca Fondazione Veronesi)
 - Main role Project: "Epigenetic control of CCRL2, a new pro-inflammatory oncosuppressor gene, in colon cancer: impact on epithelial barrier permeability". Tutor Prof. Silvano Sozzani.
In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colonic inflammation-induced carcinogenesis (AOM/DSS) with particular attention to the study of gene regulation during tumor transformation using *in vitro* and *in vivo* methods.

- Date (from – to) **January 2018-December 2018**
 - Institution Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia, Italia.
 - Position Research fellow (Borsa di Ricerca Fondazione Veronesi)
 - Main role Project: "Epigenetic control of CCRL2, a new pro-inflammatory oncosuppressor gene,

- in colon cancer: impact on epithelial barrier permeability". Tutor Prof. Silvano Sozzani. In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colonic inflammation-induced carcinogenesis (AOM/DSS) with particular attention to the study of gene regulation during tumor transformation using *in vitro* and *in vivo* methods.
- Date (from – to) **July 2017-December 2017**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia
 - Position Assegnista di Ricerca
 - Main role Project: "Role of chemokine receptors in carcinogenesis and tumor progression". Tutor Prof. Silvano Sozzani.
In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colon inflammation-induced carcinogenesis (AOM/DSS) and in genetic models (TP53/KRas) of lung cancer.
- Date (from – to) **July 2016-June 2017**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
 - Position Assegnista di Ricerca
 - Main role Project: "Role of chemokine receptors in carcinogenesis and tumor progression". Tutor Prof. Silvano Sozzani.
In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colon inflammation-induced carcinogenesis (AOM/DSS).
- Date (from – to) **June 2015-May 2016**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
 - Position Post doctoral research fellow (Borsa di Ricerca Fondazione Veronesi)
 - Main role Project: "Role of chemokine receptors in carcinogenesis and tumor progression". Tutor Prof. Silvano Sozzani.
In this project I studied the role of the CCRL2/ACKR5 receptor in mouse models of colon inflammation-induced carcinogenesis (AOM/DSS).
- Date (from – to) **October 2014-May 2015**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia
 - Position Assegnista di Ricerca
 - Main role Project: "Regulation of VEGFC production in dendritic cells". Tutor: Prof.ssa Daniela Bosisio.
- Date (from – to) **October 2013-September 2014**
 - Institution Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia
 - Position Assegnista di Ricerca
 - Main role Project: "Regulation of VEGFC production in dendritic cells". Tutor: Prof.ssa Daniela Bosisio.
- Date (from – to) **September 2010-September 2013**
 - Institution Dipartimento di Oncologia Sperimentale, IEO, Milano, Italia
 - Position Post doctoral fellow
 - Main role Project: "Role of bacteria and mucus in intestinal tumorigenesis". Laboratory directed by Dr. Maria Rescigno.
In this project I focused on the study of what was the role of the microbiota in tumor progression in a genetic model of colon cancer (APCMin mouse model)
- Date (from – to) **January 2006-May 2010**

- Institution Centre for Cancer and Inflammation, Institute of Cancer and the CR-UK Clinical Centre Barts and The London School of Medicine and Dentistry, John Vane Science Centre, London UK. Laboratorio diretto dalla Prof. Fran Balkwill.
- Position Research Assistant
- Main role My research was focused on the study of the tumor microenvironment in a mouse model of skin-induced carcinogenesis (DMBA/TPA). In particular, my study led me to focus on regulatory B cells. I was also involved in the study of the role of the CCR4 receptor in kidney cancer.

- Date (from – to) **February 2001-January 2006**
- Institution Dipartimento di Immunologia e Biologia Cellulare, Istituto di Ricerche Farmacologiche “Mario Negri”. Directed by Prof. Alberto Mantovani
- Position PhD student
- Main role

- Date (from – to) **November 2000-January 2001**
- Institution Dipartimento di Biologia, Vallisneri, Università degli Studi di Padova, Padova, Italia. CNR (Centro Nazionale delle Ricerche), Centro per lo studio delle metallo proteine, Università di Padova
- Position Post graduate student
- Main role

RESEARCH ACTIVITY

During her PhD period she studied the role of hypoxia in the differentiation and regulation of myeloid cell migration (dendritic cells, macrophages and monocytes). He has also deepened the study of the role of hypoxia in the regulation of the metastasis process of tumor cells (*Schioppa et al, JEM 2003; Mancino A, Schioppa T et al Blood 2008*). During the period spent in Prof. Sica's laboratory, the candidate was involved in the molecular and functional characterization project of both human and mouse macrophages M1 and M2 in different experimental models of tumor (*Saccani A, Schioppa T et al Cancer Res 2006; Mantovani A, Schioppa T et al Cancer Met Rev 2006; Sica A, Schioppa T et al EJC 2006; Biswas K et al Blood 2006*). During the period spent abroad at the Centre for Cancer and Inflammation, Institute of Cancer and the CR-UK Clinical Centre Barts and The London School of Medicine and Dentistry, John Vane Science Centre, a laboratory directed by Prof. Fran Balkwill (London UK), he investigated the pathogenetic role of B cells in skin carcinogenesis. In particular, the study identified a subset of B cells, regulatory B cells, as responsible for the formation of cutaneous papillomas (*Schioppa T et al PNAS 2012*). During this period she was also involved in a project whose aim was to study the effects of a CCR4 inhibitor in renal cell carcinoma. The study produced a patent (**P118375GB, September 2007**), of which he is one of the inventors, relating to the CCR4 inhibitor and the publication of an article entitled "Inhibiting the chemokine receptor CCR4 in renal cell cancer" published in the journal JCI in 2017 (*Berlato C et al JCI 2017*).

During the second postdoctoral study at the Department of Experimental Oncology at the European Oncology Institute, a laboratory directed by Dr. Maria Rescigno, she deepened the study of the role of bacteria in the process of intestinal carcinogenesis in preline models of chemically induced intestinal cancer (AOM/DSS) and in the genetic model of intestinal cancer (APCMin mice). In addition, he deepened the study of the mechanisms responsible for the modification of the composition of the microbiota during the formation and development of intestinal cancer, and the possible correlation between the condition of dysbiosis and the regulation of miRNAs that control the expression of many genes including the APC gene. The search for miRNAs was carried out both at the tissue level and at the level of biological fluids with the aim of identifying possible biomarkers (*Zagato et al Nature Microbiology, 2020*). Currently, at the Department of Molecular and Translational Medicine, he has deepened the study of the role of leukocyte recruitment in experimental models of autoimmune diseases (rheumatoid arthritis) and in the process of intestinal and pulmonary carcinogenesis, using animal genetic models, chemically induced carcinogenesis and transplantable tumor models. In this context, he studied the role of the atypical chemokine receptor CCRL2/ACKR5 in tumor progression (*Del Prete et al CIR 2019; Sozio F, Schioppa T. et al CIR 2023*).

NATIVE LANGUAGE

Italian

OTHERS LANGUAGE

English

TECHNICAL SKILLS AND EXPERTISE

In vivo work

Knowledge of regulations and ethical standards

- Knowledge of national and international regulations (es. Direttiva UE 2010/63, legislazione locale come il D.Lgs. 26/2014 in Italia).
- Understanding the principles of the 3Rs (Replacement, Reduction, Refinement) to reduce the impact on animals.
- Knowledge of drafting and presenting experimental projects to obtain the approval of ethics committees and competent authorities.

Animal handling and care

- Expertise in advanced animal management, handling and containment techniques (breeding, genotyping).
- Ability to perform complex surgeries, precise drug administration and biological sampling (isolation of tissues and organs, peripheral blood collection).
- Monitoring physiological and behavioral parameters to detect signs of distress or stress.
- Experience in defining and applying humanitarian endpoints to reduce suffering and stress.

Technical knowledge and use of tools

- Mastery of advanced in vivo imaging techniques (eg. IVIS Lumina, Intravital microscopy, endoscopies), transplant models.
- Familiarity with image analysis software (eg: Image J).

Training and certification

- Possession of accredited training (Certificazioni IZSLER nel 2022).
- Ability to train and supervise other researchers in compliance with standard procedures and best practice.

Knowledge and critical analysis of animal models

- Ability to select the most appropriate animal model to answer specific scientific questions and in-depth knowledge of the following models: recruitment of leukocytes in vivo; evaluation of tumor growth in vivo; chemical-induced carcinogenesis; genetic models of intestinal and lung cancer; experimental models of transplantable cancer; models of local inflammation to assess the effect of drug administration; bacterial infection patterns; experimental models of rheumatoid arthritis; experimental models of osteoarthritis; models of intestinal permeability. Administration of intravenous, intraperitoneal, intratracheal, retro-orbital, intramuscular and oral drugs and cell suspensions (gavage)
- Knowledge of the limitations and potentialities of animal models and their comparison with alternative models.

Multiparametric flow cytometry and cell sorting

Technical skills in advanced flow cytometry

- Theoretical and practical knowledge of multicolor flow cytometers: experience with 10+ parameter instruments, including optical and laser configurations (eight and fifteen color acquisition and analysis using instruments such as MACSQuant-Miltenyi, Canto I and II, Fortessa-BD, Symphony A5 SE-BD).
- Planning and optimization of experiments: selection and appropriate combination of fluorochromes based on spectral overlap and compensation.
- Advanced data analysis: use of specialized software (e.g., FlowJo, FCS Express) for gating, clustering, and multivariate analysis.
- Cell isolation and sorting: experience in the use of flow cytometer sorters (e.g. FACSAria) for the isolation of specific cell subpopulations.
- Protocol validation and standardization: development of appropriate controls, standardization of procedures, and assurance of experimental reproducibility.

Practical experience

- Design and management of high-complexity flow cytometry experiments, e.g. human and murine immunophenotyping studies and monitoring of immune activity.
- Cell sorting of specific populations effector of the immune system. Characterization of the expression of multiple color surface and intracellular markers. DNA content analysis. Cell proliferation assays. Apoptosis assays. Oxidative stress assays.
- Preparation and management of complex biological samples: peripheral blood, disrupted solid tissues, fixed or cryopreserved samples.
- Maintain and calibrate your instruments to ensure optimal performance and minimize downtime.

Soft Skills

- Ability to train technical personnel or students in the use of instrumentation and analysis software.
- Problem-solving and troubleshooting skills on complex instruments and experimental setups.
- Effective communication to present results and interpretations to interdisciplinary groups.

Microbiota analysis

Extraction and purification of DNA and RNA from feces and mucus. Isolation and culture of bacterial species. Preparation of lyophilized bacteria for oral administration (gavage) in experimental animals.

Microscopy

Preparation of samples for immunohistochemical and immunofluorescence analysis; Direct and indirect microscopy, confocal, time lapse, intravital microscopy.

Molecular Biology

- Purification of RNA, miRNA and DNA from tissues, cells and biological fluids; Northern Blot, RT, PCR, RACE, Real Time PCR, cloning, sequencing.
- Animal genotyping by PCR.
- Experience in the extraction of nuclear, cytoplasmic, total and their analysis by: Western Blot, ELISA, EMSA, pulse chase, chromatin immunoprecipitation (ChIP).
- Experience in the construction and amplification of plasmids (bacterial transformation and maxi, midi e mini purification).
- Transfection methods: calcium phosphate, lipids, electroporation.
- Competence in the use of siRNA/shRNA and techniques of RNA interference: stable (tetracycline inducible system) and transient (lipid and amine).
- RNA-seq e scRNA-seq: expertise in the isolation and preparation of RNA for transcriptomics studies on single cells or populations.

Cell Biology

- Cell culture manipulation: ability to handle primary cultures, immortalized cell lines, and human and murine stem cells under sterile conditions
- Purification of primary cells: isolation of mononuclear cells from buffy coat; isolation of murine and human macrophages from solid tumor and ascites.
- Migration, invasion, and transmigration assays: cell migration by Boyden microchamber and transwell; experience with tests such as the wound healing assay or Transwell.
- Cell co-cultures: ability to create multicellular systems to study interactions between different cell types (e.g. tumor and stromal cells).

Radiolabeling

Handling of radioactive tracers ³²P, ⁵¹Cr, ³⁵S. Preparation of radioactive probes for Northern blot analysis.

ORGANIZZAZIONE E PARTECIPAZIONE A CONFERENZE

IT KNOWLEDGE

Good knowledge of the Windows operating system, the Macintosh system and the Office package (Word, Excel, PowerPoint). Good knowledge of the main browsers and search engines. Good knowledge of graphic applications (PhotoShop, Paint, Illustrator) and of the analysis programs GraphPad Prism and FlowJo. Use of databases such as Oncomine, Protein Atlas, UCSC Genome Browser, BLAST.

- 2023 Congress organized by the Società Italiana Immunologia, Immunologia Clinica e Allergologia (SIICA). Oral presentation entitled "The ribonuclease T2 as new biomarker of disease activity in rheumatoid arthritis". Verona, Italia.
- 2022 Congress organized by the Società Italiana Immunologia, Immunologia Clinica e Allergologia (SIICA). Oral presentation entitled "The atypical receptor CCRL2 as a modulator of aged neutrophils homing to clearance organs". Napoli, Italia.
- 2011 Conference of American Association Cancer Research (AACR) Tumour Microenvironment Complexity: Emerging Roles in cancer Therapy. Oral presentation entitled "B regulatory cells and the tumour-promoting actions of TNF-alpha during squamous carcinogenesis". Orlando, Florida.
- 2005 Immunology for Oncologists (course ESO), Ascona, Switzerland. Oral presentation entitled "A distinct and unique M2 transcriptional programme expressed by tumor-associated macrophages: defective NF-kB and enhanced IRF-3/STAT1 activation". Ascona, Svizzera.
- 2003 and 2004 conferences organized by the Società Italiana Immunologia, Immunologia Clinica e Allergologia (SIICA). Oral presentation entitled "Regulation of the chemokine receptor CXCR4 by hypoxia". Verona e Ischia, Italia.

Conference organization: member of the organizing committee of the Milan Meets Immunology meeting (one day conference) from 2011 to 2014. (<https://milanimmunology.wordpress.com/people/>)

TEACHING ACTIVITY

- A.A. 2024/2025: Insegnamento: "Laboratorio di Patologia Clinica". Corso di Studio: 08635 - BIOTECNOLOGIE – 3° anno, presso l'Università degli Studi di Brescia. Settore: MED/05 (30 ore, 3 CFU).
- A.A. 2024/2025: Insegnamento: "Patologia Generale". Corso di Studio: 08697 - OSTETRICIA – 1° anno, presso l'Università degli Studi di Brescia. Settore: MED/04 (14 ore, 1 CFU).
- A.A. 2023/2024: Insegnamento: "Laboratorio di Patologia Clinica". Corso di Studio: 08635 - BIOTECNOLOGIE – 3° anno, presso l'Università degli Studi di Brescia. Settore: MED/05 (30 ore, 3 CFU).
- A.A. 2022/2023: Insegnamento: "Laboratorio di Patologia Clinica". Corso di Studio: 08635 - BIOTECNOLOGIE – 3° anno di corso, presso l'Università degli Studi di Brescia. Settore: MED/05 (30 ore, 3 CFU).
- A.A. 2021/2022: Insegnamento: "Modelli animali per lo studio di malattie genetiche". Corso di Studio: 08635 - BIOTECNOLOGIE – 3° anno di corso, presso l'Università degli Studi di Brescia. Settore: MED/05 (30 ore, 3 CFU).
- A.A. 2021/2022: Insegnamento: "Patologia Clinica". Corso di Studio: 08692 - DIETISTICA (abilitante alla professione sanitaria di dietista) – 1° anno di corso, presso l'Università degli Studi di Brescia. Settore: MED/05 (12 ore, 1 CFU).
- A.A. 2020/2021 erogato nell'A.A. 2021/2022: Insegnamento: "Patologia Generale", SSD MED/04, per la Scuola di Specializzazione in Ortopedia e Traumatologia (8 ore, 1 CFU), 1° anno, presso l'Università degli Studi di Brescia.

PATENTS

Inventor in the international patent Application No.PCT/GB2008/003160.

Titolo: CANCER MARKER AND THERAPEUTIC TARGET.

Publication Number WO/2009/037454 (UK patent application: P118375GB).

Applicants: CANCER RESEARCH TECHNOLOGY LTD.

Inventors: BALKWILL, Frances; SLETTENAAR, Violet; WILSON, Julia; WANG, Yaohe; **SCHIOPPA, Tiziana**.

(<https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009037454&tab=PCTBIBLIO>)

FUNDING

- Grant Fondazione Veronesi 2019. Progetto: "Epigenetic control of CCRL2, a new pro-inflammatory oncosuppressor gene, in colon cancer". at Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
- Grant Fondazione Veronesi 2018. Progetto: "Epigenetic control of CCRL2, a new pro-inflammatory oncosuppressor gene, in colon cancer". at Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
- Grant Fondazione Veronesi 2015: Progetto: "Role of the atypical chemokine receptor CCRL2 in colon cancer", at Dipartimento di Medicina Molecolare Traslazionale, Università di Brescia, Brescia, Italia.
- Progetto di ricerca AICR (American Institute for Cancer Research). Titolo del progetto: " Study of the role of endogenous and exogenous TLR4 ligands in skin carcinogenesis". At Centro Oncologico Europeo, Milano, Italia. From 01/01/2011 to 01/12/2013. **Ruolo: Co-Applicant. Finanziato.**

PARTECIPAZIONE O COORDINAZIONE DI GRUPPI DI RICERCA

- Partecipazione to research group:

- Member participating in the research project funded by AIRC (IG15811) "The atypical chemokine receptor CCRL2/ACKR5 as a new player in carcinogenesis and tumor progression", from 02/01/2015 to 31/12/2017, PI: Prof. Silvano Sozzani.
- Member participating in the research project PRIN2017: "Emerging players shaping the responses of tumor inflammatory infiltrate", PI: Prof. Silvano Sozzani.
- Member participating in the research project funded by AIRC AIRC (IG20776) "The atypical chemokine receptor CCRL2/ACKR5 as a new player in carcinogenesis and tumor progression", from 02/01/2018 to 01/01/2023, PI: Prof. Silvano Sozzani.
- Member participating in the research project PRIN2022: "We all eat microbes: diet as reservoir of microorganisms that preserve the ecosystem services of the human gastrointestinal microbiota (the µEat project)", decorrenza dal 18/10/2023 al 17/10/2025 PI: Prof. Simone Domenico Guglielmetti.

- Coordination of research group:

- PI of a research project assigned with local funds (ex-60%-2020) by Università degli Studi di Brescia dal titolo " Ruolo del nuovo oncosoppressore CCRL2 nella barriera intestinale". Other members of the research group: Ilaria Barbazza (PhD student)
- PI of a research project assigned with local funds (ex-60%-2021) by Università degli Studi di Brescia dal titolo " Ruolo del nuovo oncosoppressore CCRL2 nella barriera intestinale ". Other members of the research group: Ilaria Barbazza (PhD student)
- PI of a research project assigned with local funds (ex-60%-2022) by Università degli Studi di Brescia dal titolo " Ruolo del nuovo oncosoppressore CCRL2 nella barriera intestinale ". Other members of the research group: Mauro Passari (PhD student)
- PI of a research project assigned with local funds (ex-60%-2023) by Università degli Studi di Brescia dal titolo " Ruolo del nuovo oncosoppressore CCRL2 nella barriera intestinale ". Other members of the research group: Zucchi Giovanni.

SCIENZA DISSEMINAZIONE

- Science ambassador by Science, Technology, Engineering and Mathematics Network-STENMET (London).
- Organizer of laboratories for children of 5-10 years old in the contest of Festival di Bergamo Scienza (winner in 2015).
- Science dissemination for AIRC (Associazione Italiana per la Ricerca sul Cancro)
- Science dissemination for Fondazione Veronesi.

AWARDS

- April 2004: 1° prize SPACE” Import – Export” at the 3rd National Conference SIICA
- November 2011: AACR-Aflac Incorporated Scholar-in-Training Award at the Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy-AACR

MEMBERSHIP IN SCIENTIFIC SOCIETIES

- Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA- membro effettivo dal 2006)
- American Association for Cancer Research (AACR- dal 2007)
- SIBioC (Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio- dal 2020).

ATTIVITA' EDITORIALE

Reviewer for international scientific journal: PlosOne, Carcinogenesis, Cancer Immunology, Immunotherapy, Cancers, Frontiers in Immunology, Frontiers in Oncology, JECC (Journal of Experimental and Clinical Cancer Research), IJMS (International Journal of Molecular Science), Cell Death and Disease, Cells.

Member of the Editorial Board of the Frontiers Section in Cancer Immunity and Immunotherapy come **Associate Editor** (da Gennaio 2022)

SCIENTIFIC PUBLICATION

N° PUBLICATIONS: 36

N° total citation: 6054

H INDEX: 23 (Scopus) updated at 04/07//2025

1. Salvi V, Gaudenzi C, Mariotti B, Giongrandi G, Alacqua S, Gianello V, **Schioppa T**, Tiberio L, Ceribelli A, Selmi C, Bergese P, Calza S, Del Prete A, Sozzani S, Bazzoni F, Basisio D. Cell damage shifts the microRNA content of small extracellular vesicles into a Toll-like receptor 7-activating cargo capable to propagate inflammation and immunity. *Cell Commun Signal.* 2024 Nov 8;22(1):536. Doi: 10.1186/s12964-024-01924-z. PMID: 39516877.
2. Passari M*, Scutera S*, **Schioppa T***, Tiberio L*, Piantoni S, Tamassia N, Bugatti M, Vermi W, Angeli F, Caproli A, Salvi V, Sozio F, Gismondi A, Stabile H, Franceschini F, Basisio D, Acquati F, Vermeren S, Sozzani S, Andreoli L, Del Prete A, Musso T. Regulation of neutrophil associated RNASET2 expression in rheumatoid arthritis. *Sci Rep.* 2024 Nov 5;14(1):26820. doi: 10.1038/s41598-024-77694-y. PMID: 39500942. *Equally contributed.
3. Laffranchi M*, **Schioppa T***, Sozio F, Piserà A, Tiberio L, Salvi V, Basisio D, Musso T, Sozzani S, Del Prete A. Chemerin in immunity. *J Leukoc Biol.* 2024 Sep 4;qiae181. doi: 10.1093/jleuko/qiae181. PMID: 39228313. *Equally contributed.
4. **Schioppa T**, Gaudenzi C, Zucchi G, Piserà A, Vahidi Y, Tiberio L, Sozzani S, Del Prete A, Basisio D, Salvi V. Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells. *J Transl Med.* 2024 Jul 29;22(1):691. doi: 10.1186/s12967-024-05457-4. PMID: 39075551
5. Tiberio L, Laffranchi M, Zucchi G, Salvi V, **Schioppa T**, Sozzani S, Del Prete A, Basisio D. Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer. *Front Immunol.* 2024 Mar 5;15:1360291. doi: 10.3389/fimmu.2024.1360291. PMID: 38504978.

6. 5: Gaudenzi C, **Schioppa T**, Passari M, Zucchi G, Tiberio L, Vahidi Y, Scutera S, Musso T, Sozzani S, Del Prete A, Salvi V, Bosisio D. Extracellular microRNAs induce dendritic cell-dependent joint inflammation and potentiate osteoclast differentiation via TLR7/8 engagement. *J Autoimmun.* 2024 May;145:103189. doi: 10.1016/j.jaut.2024.103189. PMID: 38442677.
7. Girone C, Calati F, Lo Cigno I, Salvi V, Tassinari V, **Schioppa T**, Borgogna C, Lospinoso Severini L, Hiscott J, Cerboni C, Soriani A, Bosisio D, Gariglio M. The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity. *Cancer Immunol Immunother.* 2023 Sep;72(9):3097-3110. doi: 10.1007/s00262-023-03483-7. PMID: 37356050.
8. Sozio F*, **Schioppa T***, Laffranchi M, Salvi V, Tamassia N, Bianchetto-Aguilera FM, Tiberio L, Bonecchi R, Bosisio D, Parmentier M, Bottazzi B, Leone R, Russo E, Bernardini G, Garofalo S, Limatola C, Gismondi A, Sciumè G, Mantovani A, Del Prete A, Sozzani S. CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer. *Cancer Immunol Res.* 2023 Sep 1;11(9):1280-1295. doi: 10.1158/2326-6066.CIR-22-0951. PMID: 37343073. *Equally contributed.
9. **Schioppa T**, Nguyen HO, Tiberio L, Sozio F, Gaudenzi C, Passari M, Del Prete A, Bosisio D, Salvi V. Inhibition of Class I Histone Deacetylase Activity Blocks the Induction of TNFAIP3 Both Directly and Indirectly via the Suppression of Endogenous TNF- α . *Int J Mol Sci.* 2022 Aug 28;23(17):9752. doi: 10.3390/ijms23179752. PMID: 36077149.
10. **Schioppa T**, Nguyen HO, Salvi V, Maugeri N, Facchinetti F, Villetti G, Civelli M, Gaudenzi C, Passari M, Sozio F, Barbazza I, Tamassia N, Cassatella MA, Del Prete A, Bosisio D, Tiberio L. The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils. *Int J Mol Sci.* 2022 Apr 29;23(9):4982. doi: 10.3390/ijms23094982. PMID: 35563373.
11. Nguyen HO, Salvi V, Tiberio L, Facchinetti F, Govoni M, Villetti G, Civelli M, Barbazza I, Gaudenzi C, Passari M, **Schioppa T**, Sozio F, Del Prete A, Sozzani S, Bosisio D. The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation. *J Transl Med.* 2022 May 10;20(1):203. doi: 10.1186/s12967-022-03402-x. PMID: 35538539.
12. Nguyen HO, **Schioppa T**, Tiberio L, Facchinetti F, Villetti G, Civelli M, Del Prete A, Sozio F, Gaudenzi C, Passari M, Barbazza I, Sozzani S, Salvi V, Bosisio D. The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs. *Front Immunol.* 2022 Jan 24;12:797390. doi: 10.3389/fimmu.2021.797390. PMID: 35140709.
13. Salvi V, Nguyen HO, Sozio F, **Schioppa T**, Gaudenzi C, Laffranchi M, Scapini P, Passari M, Barbazza I, Tiberio L, Tamassia N, Garlanda C, Del Prete A, Cassatella MA, Mantovani A, Sozzani S, Bosisio D. SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. *JCI Insight.* 2021 Sep 22;6(18):e150542. doi: 10.1172/jci.insight.150542. PMID: 34375313.
14. Scutera S, Mitola S, Sparti R, Salvi V, Grillo E, Piersigilli G, Bugatti M, Alotto D, **Schioppa T**, Sozzani S, Musso T. Bartonella henselae Persistence within Mesenchymal Stromal Cells Enhances Endothelial Cell Activation and Infectibility That Amplifies the Angiogenic Process. *Infect Immun.* 2021 Jul 15;89(8):e0014121. doi: 10.1128/IAI.00141-21. Epub 2021 Jul 15. PMID: 34031126.
15. Caronni N, Piperno GM, Simoncello F, Romano O, Vodret S, Yanagihashi Y, Dress R, Dutertre CA, Bugatti M, Bourdeley P, Del Prete A, **Schioppa T**, Mazza EMC, Collavin L, Zacchigna S, Ostuni R, Guermontprez P, Vermi W, Ginhoux F, Bicciato S, Nagata S, Benvenuti F. TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses.

- Nat Commun. 2021 Apr 14;12(1):2237. doi: 10.1038/s41467-021-22535-z. PMID: 33854047.
16. Sozio F, **Schioppa T**, Sozzani S, Del Prete A. Urethane-induced lung carcinogenesis. *Methods Cell Biol.* 2021;163:45-57. doi: 10.1016/bs.mcb.2020.09.005. PMID: 33785168.
 17. **Schioppa T**, Sozio F, Barbazza I, Scutera S, Bosisio D, Sozzani S, Del Prete A. Molecular Basis for CCRL2 Regulation of Leukocyte Migration. *Front Cell Dev Biol.* 2020 Dec 10;8:615031. doi: 10.3389/fcell.2020.615031. PMID: 33363177.
 18. Del Prete A, Sozio F, Barbazza I, Salvi V, Tiberio L, Laffranchi M, Gismondi A, Bosisio D, **Schioppa T**, Sozzani S. Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications. *Int J Mol Sci.* 2020 May 30;21(11):3930. doi: 10.3390/ijms21113930. PMID: 32486257.
 19. Zagato E, Pozzi C, Bertocchi A, **Schioppa T**, Saccheri F, Guglietta S, Fosso B, Melocchi L, Nizzoli G, Troisi J, Marzano M, Oresta B, Spadoni I, Atarashi K, Carloni S, Arioli S, Fornasa G, Asnicar F, Segata N, Guglielmetti S, Honda K, Pesole G, Vermi W, Penna G, Rescigno M. Endogenous murine microbiota member *Faecalibaculum rodentium* and its human homologue protect from intestinal tumour growth. *Nat Microbiol.* 2020 Mar;5(3):511-524. doi: 10.1038/s41564-019-0649-5. PMID: 31988379.
 20. Del Prete A, Sozio F, **Schioppa T**, Ponzetta A, Vermi W, Calza S, Bugatti M, Salvi V, Bernardini G, Benvenuti F, Vecchi A, Bottazzi B, Mantovani A, Sozzani S. The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance. *Cancer Immunol Res.* 2019 Nov;7(11):1775-1788. doi: 10.1158/2326-6066.CIR-19-0168. PMID: 31484658.
 21. Tiberio L, Del Prete A, **Schioppa T**, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. *Cell Mol Immunol.* 2018 Apr;15(4):346-352. doi: 10.1038/s41423-018-0005-3. PMID: 29563613.
 22. Del Prete A, **Schioppa T**, Tiberio L, Stabile H, Sozzani S. Leukocyte trafficking in tumor microenvironment. *Curr Opin Pharmacol.* 2017 Aug;35:40-47. doi: 10.1016/j.coph.2017.05.004. PMID: 28577499.
 23. Berlato C, Khan MN, **Schioppa T**, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. *J Clin Invest.* 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. PMID: 28134623.
 24. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, **Schioppa T**, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group; Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. *Cancer Res.* 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. PMID: 22065722.
 25. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, **Schioppa T**, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirstrom K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR. Interleukin-6 as a therapeutic target in human ovarian cancer. *Clin Cancer Res.* 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. PMID: 21795409.
 26. **Schioppa T**, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR. B regulatory cells and the tumor-promoting actions of TNF- α during squamous carcinogenesis. *Proc Natl Acad Sci U S A.* 2011 Jun 28;108(26):10662-7. doi: 10.1073/pnas.1100994108. PMID: 21670304.

27. Toulza F, Nosaka K, Tanaka Y, **Schioppa T**, Balkwill F, Taylor GP, Bangham CR. Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. *J Immunol*. 2010 Jul 1;185(1):183-9. doi: 10.4049/jimmunol.0903846. PMID: 20525891.
28. Mancino A, **Schioppa T**, Larghi P, Pasqualini F, Nebuloni M, Chen IH, Sozzani S, Austyn JM, Mantovani A, Sica A. Divergent effects of hypoxia on dendritic cell functions. *Blood*. 2008 Nov 1;112(9):3723-34. doi: 10.1182/blood-2008-02-142091. PMID: 18694997.
29. Saccani A*, **Schioppa T***, Porta C*, Biswas SK*, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. *Cancer Res*. 2006 Dec 1;66(23):11432-40. doi: 10.1158/0008-5472.CAN-06-1867. PMID: 17145890. *Equally contributed.
30. Mantovani A, **Schioppa T**, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. *Cancer Metastasis Rev*. 2006 Sep;25(3):315-22. doi: 10.1007/s10555-006-9001-7. PMID: 16967326.
31. Sica A, **Schioppa T**, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. *Eur J Cancer*. 2006 Apr;42(6):717-27. doi: 10.1016/j.ejca.2006.01.003. PMID: 16520032.
32. Biswas SK, Gangi L, Paul S, **Schioppa T**, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). *Blood*. 2006 Mar 1;107(5):2112-22. doi: 10.1182/blood-2005-01-0428. PMID: 16269622.
33. Mantovani A, Sozzani S, Locati M, **Schioppa T**, Saccani A, Allavena P, Sica A. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Novartis Found Symp*. 2004;256:137-45; discussion 146-8, 259-69. PMID: 15027487.
34. Mantovani A, **Schioppa T**, Biswas SK, Marchesi F, Allavena P, Sica A. Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. *Tumori*. 2003 Sep-Oct;89(5):459-68. doi: 10.1177/030089160308900501. PMID: 14870765.
35. **Schioppa T**, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G, Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia. *J Exp Med*. 2003 Nov 3;198(9):1391-402. doi: 10.1084/jem.20030267. PMID: 14597738.
36. Locati M, Otero K, **Schioppa T**, Signorelli P, Perrier P, Baviera S, Sozzani S, Mantovani A. The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. *Allergy*. 2002 Nov;57(11):972-82. doi: 10.1034/j.1398-9995.2002.02166.x. PMID: 12358993.